Prevention of Ebola virus disease through vaccination: where we are in 2018

Lévy, Yves; Lane, Clifford; Piot, Peter; Beavogui, Abdul Habib; Kieh, Mark; Leigh, Bailah; Doumbia, Seydou; D’Ortenzio, Éric; Lévy-Marchal, Claire; Pierson, Jerome F.; Watson-Jones, Deborah; Nguyen, Vinh Kim; Larson, Heidi; Lysander, Julia; Lacabaratz, Christine; Thiébaut, Rodolphe; Augier, Augustin; Ishola, David; Kennedy, Stephen B.; Chêne, Geneviève; Greenwood, Brian; Neaton, James D.; Yazdanpanah, Yazdan

doi:10.1016/s0140-6736(18)31710-0

Cited by 102 publications

(43 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,19 Widespread adverse events and questionable efficacy in human populations of rVSV-EBOV may represent existing gaps in VSV-vectored vaccine approaches. [20][21][22] However, replication-defective single-cycle recombinant vesicular stomatitis viruses (VSVΔG) pseudotyped with either NiV F or G showed protection against 1000 times LD 50 NiV challenge in Syrian golden hamsters after a single dose inoculation, offering a distinct safety advantage over the live-attenuated rVSV-ZEBOV-GP-NiVG. 18 Nonetheless, production requires multiple plasmid transfections which can be costly for large-scale manufacturing.…”

Section: Introductionmentioning

confidence: 99%

Rabies-based vaccine induces potent immune responses against Nipah virus

et al. 2019

View full text Add to dashboard Cite

Nipah Virus (NiV) is a re-emerging zoonotic pathogen in the genus Henipavirus of the Paramyxoviridae family of viruses. NiV is endemic to Bangladesh and Malaysia and is highly fatal to both livestock and humans (human case fatality rate = 74.5%). Currently, there is no approved vaccine against NiV on the market. The goal of this study was to use a recombinant RABV vector expressing NiV glycoprotein (NiV G) to develop a bivalent candidate vaccine against NiV disease and rabies virus (RABV) disease, which is also a significant health burden in the regions where NiV is endemic. The rabies vector is a well-established vaccine strain that lacks neurovirulence and can stably expresses foreign antigens that are immunogenic in various animal models. Mice inoculated intranasally with the live recombinant RABV/NiV vaccine (NIPARAB) showed no signs of disease. To test the immunogenicity of the vaccine candidate, groups of C57BL/6 mice were immunized intramuscularly with a single dose of live vaccine particles or two doses of chemically inactivated viral particles. Both vaccination groups showed NiV G-specific seroconversion, and the inactivated (INAC) vaccine group yielded higher titers of NiV G-specific antibodies. Furthermore, cross-reactivity of NiV G-specific immune sera against Hendra virus (HeV), was confirmed by immunofluorescence (IF) and indirect ELISA against soluble recombinant HeV glycoprotein (HeV G). Both live and killed vaccines induced neutralizing antibodies. These results indicate that NIPARAB may be used as a killed virus vaccine to protect humans against NiV and RABV, and possibly as a preventative measure against HeV as well.

show abstract

Section: Introductionmentioning

confidence: 99%

Rabies-based vaccine induces potent immune responses against Nipah virus

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Vaccination development is in place, but there is currently no Federal Drug Administration (FDA) approved vaccination for Ebola. Currently, there are 14 different clinical trials running with the goal of developing a safe and effective Ebola vaccine [74]. An investigational vaccine called rVSV-ZEBOV is presently being used in DRC under "compassionate use".…”

Section: Vaccinationmentioning

confidence: 99%

The Emerging Threat of Ebola

LaBrunda

Amin

2020

Advanced Sciences and Technologies for Security Applications

View full text Add to dashboard Cite

“…Treatment of Ebola virus disease is supportive, and no anti‐viral drugs have proven to be effective. A vaccine expressing EBOV surface glycoprotein in a recombinant vesicular stomatitis virus vector was implemented in three phase II/III trials across West Africa in 2015 . These trials were designed to deliver the vaccine to high‐risk populations, while also evaluating safety and efficacy data.…”

Section: Ebola Virus Diseasementioning

confidence: 99%

“…A vaccine expressing EBOV surface glycoprotein in a recombinant vesicular stomatitis virus vector was implemented in three phase II/III trials across West Africa in 2015. 69 These trials were designed to deliver the vaccine to high-risk populations, while also evaluating safety and efficacy data. In Sierra Leone, almost 8000 participants were immunized in a randomized, non-blinded, ring-vaccination trial without placebo.…”

Section: Overview Of Ebola Virus Diseasementioning

confidence: 99%

Emerging infectious uveitis: Chikungunya, dengue, Zika and Ebola: A review

Oliver

Carr

Smith

2019

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Recently recognized forms of uveitis include intraocular inflammations that occur during or following one of several emerging infectious diseases: chikungunya fever, dengue, Zika virus disease and Ebola virus disease. Anterior, intermediate, posterior and pan‐uveitis have been described in individuals infected with chikungunya virus. Persons who contract dengue or Zika viruses also may develop different types of uveitis in the course of the infection: maculopathy is a common manifestation of dengue eye disease, and Zika eye disease may cause hypertensive anterior uveitis or mimic a white dot syndrome. Up to one‐third of Ebola survivors develop aggressive uveitis, which is frequently associated with vision loss and complicated by cataract. There are no specific anti‐viral drugs for these forms of uveitis, and thus treatment is largely supportive. In this article, we summarize the systemic infectious diseases and virology, and describe the clinical presentations, outcomes and management of emerging viral forms of uveitis.

show abstract

Prevention of Ebola virus disease through vaccination: where we are in 2018

Cited by 102 publications

References 29 publications

Rabies-based vaccine induces potent immune responses against Nipah virus

Rabies-based vaccine induces potent immune responses against Nipah virus

The Emerging Threat of Ebola

Emerging infectious uveitis: Chikungunya, dengue, Zika and Ebola: A review

Contact Info

Product

Resources

About